Noninvasive markers of fibrosis in chronic hepatitis patients

Journal of Clinical Gastroenterology

Volumn 40, Issue 6, 2006, Pages 461-463

  Pockros, Paul J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BLEEDING; CHRONIC HEPATITIS; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DEATH; EDITORIAL; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; PEER REVIEW; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SOCIOECONOMICS; VALIDATION PROCESS;

ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; HEPATITIS, CHRONIC; HUMANS; LIVER FUNCTION TESTS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 33748260160     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200607000-00001     Document Type: Editorial

References (28)

1. Castera l, Negre I, Samii K, et al. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30:1529-1530.
2. Bravo A, Sheth S, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
3. Bedossa P, Dargere D, Paradise V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-1457.
4. Regev A, Berho M, Jeffers L, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.
5. Bonacini M, Hadi G, Govindarajan S, et al. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C infection. Am J Gastroenterol. 2001;92:1302-1304.
6. Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C infection. Am J Gastroenterol. 2001;96:3142-3146.
7. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93:44-48.
8. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
9. Imbert-Bismut F, Ratziu V, Picroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.
10. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-992.
11. Sud A, Hui J, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology. 2004;39:1239-1247.
12. Assy N, Minuk GY. Serum aspartate but not alanine transferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol. 2000;95:1545-1550.
13. Park GJ, Lin BP, Ngu MC, et al. Aspartate aminotransferase: aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol. 2000;15:386-390.
14. Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol. 2000;95:2328-2332.
15. Adams L, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873.
16. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373-1381.
17. Snyder N, Gajula L, Xiao S-Y, et al. APRI: an easy and validated predictor of hepatic fibrosis is chronic hepatitis C. J Clin Gastroenterol. 2006;40:535-542.
18. Giannini E, Zaman A, Ceppa P, et al. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol. 2006;40:521-527.
19. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in persons infected by Hepatitis C Virus: longitudinal validation in a randomized trial. J Viral Hepatitis. 2002;9:128-133.
20. Poynard T, McHutchinson J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alpha 2b and ribavirin. Hepatology. 2003;38:481-492.
21. Poynard T, Imber-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comparative Hepatol. 2004;3:8.
22. Poynard T, Muntanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem. 2004;10:10.
23. Naveau S, raynard B, Ratziu V et al. Biomarkers for the prediction of liver fibrosis in patients with alcoholic liver disease. Clin Gastroenterol Hepatol. 2005;3:167-174.
24. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of Transient Elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-350.
25. Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005;100:1970-1980.
26. Patel K, Gordon S, Jacobson I, et al. Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-toadavanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004;41:935-942.
27. Calvez S, Thabut D, Messous D, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology. 2004;39:862-863.
28. Lok A, Wai C-T. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C: reply. Hepatology. 2004;39:863.